VBI Vaccines — Investor Presentation (November 2018)
32 slides from VBI Vaccines's investor presentation, Nov 14, 2018
Slide 1: Corporate Presentation
iy Ma, 2 VBI VACCINES "Wr CORPORATE PRESENTATION NASDAQ: VBIV NOVEMBER 2018
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
eee Cautionary Statement Regarding Forward-Looking Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
Slide 3: VBI Overview
Wiyy Az . =voi- Overview anual ¢ Leveraging significant vaccinology expertise to address unmet medical needs in both INFECTIOUS DISEASE and IMMUNO-ONCOLOGY * Advancing prevention of HEPATITIS B with Sci-B-Vac®, the only commercially-approved trivalent Hepatitis B vaccine — approved in 10 countries w
Slide 4: VBI Vaccines Pipeline
VBI Vaccines Pipeline Multiple Opportunities in Infectious Disease and Oncology LEAD PRE-CLINICAL PHASE! = PHASEIl_ = PHASEIII_ APPROVED STATUS INFECTIOUS DISEASE Ongoing Phase III, Topline Phase Ill data expected mid-2019 Sci-B-Vac® (Hepatitis B) (Approved in 11 countries) crn IMMUNO-ONCOLOGY Final
Slide 5: Recent Key Achievements
Recent Key Achievements OCTOBER 2017 — NOVEMBER 2018 November 2018 Announcement of early data from Phase I/Ila study of VBI-1901 in recurrent GBM patients October 2018 Completion of vaccination in PROTECT Phase III study for Sci-B-Vac® (Hepatitis B) September 2018 Announcement of formation of new Sc
Slide 6: Sci-B-Vac
SCI-B-VAC® Only commercially-available trivalent vaccine containing pre-S1, pre-S2, and S antigens of Hepatitis B virus nal NASDAQ: VBIV 6
Slide 7: Sci-B-Vac: Importance of Trivalent Conformation
Sci-B-Vac® : Importance of Trivalent Conformation Sci-B-Vac® achieves rapid onset of protection and higher seroprotection rates, at a lower dosage than competing vaccines 2% GENERATION VACCINES SCI-B-VAC® Viral antigens mimicked: SProtein @ wf Vv Pre-Sl1 Vv Pre-s2. Vv Adjuvant: Next-generation Adj.
Slide 8: Hepatitis B Unmet Need: Low Vaccination Rates
OOO eee Hepatitis B Unmet Need : Low Vaccination Rates Reported US H ination Coverage — 2015 (2 3 doses) Otherwise Healthy Adults aged 2 19 years 24.6% Adults aged 19-49 years 32.0% Adults age 2 50 years 16.5% High-Risk Chronic Liver Conditions 27.4% Diabetics — Age 19-59 years 24.4% Diabetics — Age
Slide 9: Hepatitis B Unmet Need: High-Risk Populations
Hepatitis B Unmet Need : High-Risk Populations SEROCONVERSION RATES WITH CURRENT VACCINES FALL DRAMATICALLY WITHIN THE ELDERLY AND HIGH-RISK PATIENT POPULATIONS Anti-HBs Seroconversion Rates After Hepatitis B Vaccination Neonates >95% Age 2-19 ~99% Age 20 - 29 ~95% Age 30 - 39 ~90% Age 40 - 49 ~85%
Slide 10: Extensive Existing Efficacy and Safety Data Package
OOOO eee Extensive Existing Efficacy and Safety Data Package * Currently approved in 10 countries worldwide, most notably used in Israel * Commercial product distribution data estimates that over 500,000 infants and adults have been safely vaccinated with the current formulation of Sci-B-Vac® * Inth
Slide 11: Sci-B-Vac Demonstrated Superior Seroprotection Rate in Older Adults
Sci-B-Vac® Demonstrated Superior Seroprotection Rate in Older Adults Stratification by Age Demonstrated Significantly Improved Potency @ in Older Adults Seroprotection Stratified by Age Percent HBsAg Seroprotection 100.0% 95.0% 90.0% 85.0% 80.0% 75.0% 70.0% 65.0% 60.0% 55.0% 50.0% = = EE 7 Engerix B
Slide 12: Interim Data from Israeli Phase IV Study
Interim Data from Israeli Phase IV Study Reinforces Strength of Sci- B-Vac® Potency in Adult Populations & Potential for Rapid Seroprotection SCI-B-VAC® PHASE IV STUDY IN ISRAELI ADULTS (AGE 18-40, N=88) SEROPROTECTION (>10 IU/ML) 100% 80% 60% 40% 20% 0% Month 1 Month 2 Month 3 30-days post 1* vacci
Slide 13: Ongoing Phase III Clinical Program
Ongoing Phase III Clinical Program to Support Licensure in U.S., Europe, and Canada * Target Population: ~4,500 adults age 18 years and older * Clinical Trial Sites: ~40 sites across the US, Europe, and Canada * Design: Two concurrent Phase Ill studies: 1. PROTECT : Safety and immunogenicity study (
Slide 14: CMV eVLP Vaccine Pipeline
CMV eVLP Vaccine Pipeline Vaccine candidates, derived from eVLP platform technology, potently express CMV antigens to address a number of unmet medical needs Dual NASDAQ: VBIV 4
Slide 15: eVLPs are a 3rd-Generation Class of Synthetic Vaccines
OOOO eee eVLPs are a 3'*-Generation Class of Synthetic Vaccines = eVLPs are the same size and structure as enveloped viruses, presenting antigens in their natural state for an improved immune response = The foundation of the eVLP Platform is a stable, protein-based core which has the flexibility to
Slide 16: Impact and Risks of Cytomegalovirus (CMV)
OOOO eee Impact and Risks of Cytomegalovirus (CMV) Birth Defects (Congenital Infection): Solid Tumors: * Congenital CMV is the leading cause of birth defects * 90%+ of some solid tumors, incl. glioblastomas, worldwide breast cancers, and medulloblastomas are CMV+ + A first exposure during pregnancy
Slide 17: Two Candidates from Innovative eVLP Platform Technology
Two Candidates from Innovative eVLP Platform Technology Target CMV-Associated Indications i gB Envelope Antigen 7 Modified gB-G Unmodified gB pp65 Antigen VBI-1501 VBI-1901 Attributes Monovalent gB-G for Prevention Bivalent — pp65 + gB for of Infectious Disease Indications Therapeutic Immuno-Oncolog
Slide 18: eVLP Presentation Improves CMV Vaccine Potency
eVLP Presentation Improves CMV Vaccine Potency Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein PRECLINICAL RESULTS Neutralizing antibody titers for mice immunized SL 7 . with comparable doses of Recombinant gB of ¢ Neut
Slide 19: VBI-1501: Congenital CMV Phase I Study Overview
VBI-1501 : Congenital CMV Phase | Study Overview STUDY DESIGN * Target Population: 128 CMV-Negative Healthy Adults (18-40 yrs) * Design: 5-arm study, staggered Enrollment with Vaccinations at 0, 2, and 6 Months © Placebo : Empty eVLP 0.5p1g VBI-1501A : 0.5ug of gB-G w/ adjuvant alum 1.0pg VBI-1501 :
Slide 20: VBI-1501 Phase I Results: gB Antibody Binding Titers
OOOO eee VBI-1501 Phase | Results : gB Antibody Binding Titers @ Anti-gB Endpoint Titer (1/X) -® VBI-1501A (2ug gB) 4 VBI-1501A (1ug 9B) -F VBI-1501A (0.5ug gB) & VBI-1501 (1g) 105: 104 103 0 28 56 84 112 140 168 196 224 252 280 308 336 Days t t t Vaccine immunizations NASDAQ: VBIV 20
Slide 21: Neutralizing Antibody Seroconversion Rates
OOO eee Neutralizing Antibody Seroconversion Rates FIBROBLAST CELLS: ¢ 2.0ug VBI-1501A induced an 85% fibroblast cell nAb response after the 2™¢ dose and a 100% nAb response after the 34 dose * The GMT for CMV* sera was 237 (Cl: 140,400) and for the 2ug dose of VBI- 1501A was 174 (Cl: 109, 276) EPIT
Slide 22: Summary of Final Phase I Study Results
OOO eee Summary of Final Phase | Study Results * VBI-1501 is safe and well tolerated at all doses tested, with and without the adjuvant alum, with no concern about evaluating VBI-1501A at higher doses ¢ VBI-1501A is immunogenic, even at a low dose © gB antibody binding titers induced at all dose lev
Slide 23: VBI-1901 (GBM): CMV as a Foreign Viral Antigen
VBI-1901 (GBM) : CMV as a Foreign Viral Antigen Approach to Immuno-Oncology Poor Immunogenicity of Traditional Tumor-Associated Antigens (TAAs) has Limited Past Therapeutic Cancer Vaccines IMMUNOGENICITY S)
Slide 24: VBI-1901: Rationally-Designed Immuno-Therapeutic Vaccine
VBI-1901 : Rationally-Designed Immuno-Therapeutic Vaccine for CMV+ Solid Tumors Schematic Virus-like structure stimulated innate immunity & promotes uptake by Antigen Presenting Cells (APCs) Antibody Target gB T Cell Targets gB (CD4*), pp65 (CD8*) Treatment of CMV+ glioblastoma, breast Tsteet Indica
Slide 25: GBM Phase I/IIa Clinical Study Design
GBM Phase I/Ila Clinical Study Design TWO-PART, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF VBI-1901 IN PATIENTS WITH RECURRENT GBM (RGBM) Patient Treatment: + Vaccinations every 4 weeks until tumor progression + Safety visit/immunogenicity measure: 2 weeks post each vaccination + MRI: at scr
Slide 26: GBM Phase I/IIa Clinical Study: Early Data (1)
GBM Phase I/Ila Clinical Study : Early Data (1) Early immunologic data from the low- and intermediate-dose cohorts illustrate robust boosting of CMV-specific immunity directed against multiple antigens in some subjects LOW-DOSE COHORT (0.4pg) : + January — April 2018 : 6 patients enrolled + 6-month
Slide 27: GBM Phase I/IIa Clinical Study: Early Data (2)
GBM Phase I/Ila Clinical Study : Early Data (2) INTERMEDIATE-DOSE COHORT (2.0yg) : + June-August 2018 : 6 patients enrolled + Study sites expanded to include Dana Farber Cancer Institute and Massachusetts General Hospital September 14 2018 : DSMB review of all safety data and recommended continuatio
Slide 28: Summary
Summary nal NASDAQ: VBIV 28
Slide 29: VBI Vaccines Leadership
BOARD OF DIRECTORS MANAGEMENT @ VBI Vaccines Leadership Jeff Baxter THE President & CEO fosk]) COLUMN Gasminxine GROUP Dr. David Anderson, Ph.D. HARVARD Chief Scientific Officer Dr. Francisco Diaz-Mitoma, M.D., Ph.D. Chief Medical Officer Wir Chris McNulty Tenor Chief Financial Officer gerzyme @ | H
Slide 30: VBI Vaccines Global Footprint
VBI Vaccines Global Footprint North HEADQUARTERS — CAMBRIDGE, MA = CEO, CSO, CFO, CBO + 3 FTEs = Central location in biotechnology hub RESEARCH OPERATIONS — OTTAWA, CANADA = CMO, Finance + 25 FTEs = World-class R&D team and facility MANUFACTURING FACILITY — REHOVOT, ISRAEL = ©70 FIEs = GMP manufactu
Slide 31: Summary: Key Value Drivers
eae Summary KEY VALUE DRIVERS: @ Sci-B-Vac®: Phase III Program in the U.S., Europe, and Canada * Mid-Year 2019 — Topline results expected from PROTECT * Around 2019 year-end — Topline results expected from CONSTANT 0) CMV: Phase | Clinical Study * Q4 2018 — Ongoing discussions with regulatory bodies
Slide 32: VBI Vaccines Inc.
VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com